Synthetic hypericin

Small molecule

Phase 3topline reported

Evidence outlook · registrational

Topline reported 2026-04-28

Its supporting mid-stage studies have completed. The sponsor reported topline results on 2026-04-28 (FLASH2 Phase 3 interim analysis: halted for futility). The announcement is listed under Regulatory events.

Development in Cutaneous T-Cell Lymphoma stopped (2026-06) after a negative readout. Development continues in another indication. Source

Development in Psoriasis stopped (2026-11-06) for financing reasons. Source

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT06470451 · Soligenix
2025-01-07 – 2026-05-22 · CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma
What this study did
Phase 2 (4)
Other / comorbidity
NCT05872854 · Ellen Kim, MD
2023-08-21 – 2025-12-22 · Cutaneous T Cell Lymphoma, Mycosis Fungoides
What this study did
NCT06149247 · Soligenix
2023-12-05 – 2024-06-27 · Cutaneous T-Cell Lymphoma/Mycosis Fungoides
What this study did
NCT05380635 · Soligenix
2022-05-09 – 2022-08-16 · Cutaneous T-Cell Lymphoma/Mycosis Fungoides
What this study did
Phase 1 (2)
Other / comorbidity
NCT00000792 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 1995-01 · HIV Infections
What this study did
NCT00000645 · National Institute of Allergy and Infectious Diseases (NIAID)
est. completion 1994-10 · HIV Infections
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 April 2026Topline resultFLASH2 Phase 3 interim analysis: halted for futility
17 December 2025Topline resultPhase 2a Cohort 3 top-line results for SGX302 in psoriasis